The present study aimed to investigate how menopausal symptoms are related to different stages of postmenopausal years. The study participants (n = 715) were divided into four groups based on the quartile values of their years after menopause – Stage 1(1 – 2 years), Stage 2 (>2 – 5 years), Stage 3 (>5 – 9 years), and Stage 4 (>9 years). Menopausal symptoms were grouped into three domains namely physical, urinary and vaginal. We applied Correspondence Analysis to determine the interdependent relationship between menopausal symptoms and postmenopausal stages. The highest canonical correlation was observed between vaginal domain and menopausal stages. Participants who were at menopausal stages 3 and 4 independently showed proximity with vasomotor symptoms and urge incontinence; and those at stages 1 and stages 2 were more prone to physical symptoms. Arthralgia is recognized in early menopausal life, however its intensity increased with increase in menopausal age. The prevalence of urogenital atrophy increased with increase in postmenopausal years.
Al-SafiZ. A., & SantoroN. (2014). Menopausal hormone therapy and menopausal symptoms. Fertility Sterility, 101(4), 905–15. https://doi.org/10.1016/j.fertnstert.2014.02.032
2.
BarnabeiV. M., GradyD., StovallD. W., CauleyJ. A., LinF., StuenkelC. A., StefanickM. L., & PickarJ. H. (2002). Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstetrics and Gynecology, 100(6), 1209–1218.
3.
BarnabeiV. M., CochraneB. B., AragakiA. K., NygaardI., WilliamsR. S., McGovernP. G., YoungR. L., WellsE. C., O’SullivanM. J., ChenB., SchenkenR., & JohnsonS. R. (2005). Women’s health initiative investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the women’s health initiative. Obstetrics and Gynecology, 105(5), 1063–1073. https://doi.org/10.1097/01.AOG.0000158120.47542.18
4.
BodhareT. N., ValsangkarS., & BeleS. D. (2010). An epidemiological study of urinary incontinence and its impact on quality of life among women aged 35 years and above in a rural area. Indian Journal of Urology, 26(3), 353–358.
5.
BrotmanR.M., ShardellM. D., GajerP., FadroshD., ChangK., SilverM., ViscidiR. P., BurkeA. E., RavelJ., & GravittP. E. (2014). Association between the vaginal microbiota, menopause status and signs of vulvovaginal atrophy. Menopause, 21(5), 450–458. https://doi.org/10.1097/GME.0b013e3182a4690b
6.
BrunnerR. L., AragakiA., BarnabeiV., CochraneB. B., GassM., HendrixS., LaneD., OckeneJ., WoodsN. F., YasmeenS., & StefanickM. (2010). Menopausal symptom experience before and after stopping estrogen therapy in the women’s health initiative randomized, placebo-controlled trial. Menopause, 17(5), 946–954. https://doi.org/10.1097/gme.0b013e3181d76953
7.
ChirawatkulS., & MandersonL. (1994). Perceptions of menopause in northeast Thailand: Contested meaning and practice. Social Science and Medicine, 39(11), 1545–1555.
8.
ChompootweepS., TankeyoonM., YamaratK., PoomsuwanP., & DusitsinN. (1993). The menopausal age and climacteric complaints in Thai women in Bangkok. Maturitas, 17(1), 63–71. https://doi.org/10.1016/0378-5122(93)90124-Z
9.
DasguptaD., & RayS. (2015). Vasomotor and urogenital problems at midlife: A study on rural and urban women in India. Annals of Human Biology, 42(3), 268–275.
10.
DasguptaD., PalB., & RayS. (2016a). Pattern of clustering of menopausal problems: A study with a Bengali Hindu ethnic group. Journal of Women and Aging, 28(5), 363–371. https://doi.org/10.1080/08952841.2015.1018026
11.
DasguptaD., PalB., & RayS. (2016b). Factors that discriminate age at menopause: A study of Bengali Hindu women of West Bengal. American Journal of Human Biology, 27(5), 710–715. https://doi.org/10.1002/ajhb.22698
12.
Dominguez-RodriguezA., Blanco-PalaciosG., & Abreu-GonzalezP. (2011). Increased heart rate and atherosclerosis: potential implications of ivabradine therapy. World Journal of Cardiology, 3(4), 101–104. https://doi.org/10.4330/wjc.v3.i4.101
13.
FreemanE. W., SammelM. D., & SandersR. J. (2014). Risk of long-term hot flashes after natural menopause: Evidence from the Penn ovarian aging study cohort. Menopause, 21(9), 924–932. https://doi.org/10.1097/GME.0000000000000196
14.
GenazzaniA. R., SchneiderH. P. G., PanayN., & NijlandE. A. (2006). The European menopause survey 2005: Women’s perceptions on the menopause and post menopause hormone therapy. Gynecolical Endocrinology, 22(7), 369–375. https://doi.org/10.1080/09513590600842463
15.
GoldE. B., ColvinA., AvisN., BrombergerJ., GreendaleG. A., PowellL., SternfeldB., & MatthewsK. (2006). Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of women’s health across the nation. American Journal of Public Health, 96(7), 1226–1235. https://doi.org/10.2105/AJPH.2005.066936
16.
HarlowS. D., GassM., HallJ. E., LoboR., MakiP., RebarR. W., ShermanS., SlussP. M., VilliersT. (2012). For the STRAW + 10 collaborative group. Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. The Journal of Clinical Endocrinology and Metabolism, 97(4), 1159–1168, https://doi.org/10.1210/jc.2011-3362
17.
HuangK. E., XuL., NasirN. I., & JaisamrarnU. (2010). The Asian menopause survey: Knowledge, perceptions, hormone treatment and sexual function. Maturitas, 65(3), 276–283. https://doi.org/10.1016/j.maturitas
18.
Indian Institute of Population Sciences (IIPS), & ORC Macro. (2007). National Family and Health Survey-3, 2005–2006 (Vol. 1). IIPS.
19.
JehanS., Jean-LouisG., ZiziF., AugusteE., Pandi-PerumalS. R., GuptaR., AttarianH., McFarlaneS. I., HardelandR., & BrzezinskiA. (2017). Sleep, melatonin, and the menopausal transition: What are the links? Sleep Science, 10(1), 11–18. https://doi.org/10.5935/1984-0063.20170003
20.
JonesH. J., HuangA. J., SubakL. L., BrownJ. S., & LeeK. A. (2016). Bladder symptoms in the early menopausal transition. Journal of Women Health, 25(5), 457–463. https://doi.org/10.1089/jwh.2015.5370
21.
LizcanoF., & GuzmánG. (2014). Estrogen deficiency and the origin of obesity during menopause. BioMed Research International, 757461. https://doi.org/10.1155/2014/757461
22.
Mac BrideM. B., RhodesD. J., & ShusterL. T. (2010). Concise review for clinicians. Vulvovaginal atrophy. Mayo Clinic Proceedings, 85(1), 87–94. https://doi.org/10.4065/mcp.2009.0413
MahajanN., AggarwalM., & BaggaA. (2012). Health issues of menopausal women in North India. Journal of Mid-life Health, 3(2), 84–87. https://doi.org/10.4103/0976-7800.104467
25.
NappiR., SeracchioliR., SalvatoreS., CagnacciA., Di PaolantonioT., & BusaccaM. (2019). Impact of vulvovaginal atrophy of menopause: Prevalence and symptoms in Italian women according to the EVES study. Gynecological Endocrinology, 1–7. https://doi.org/10.1080/09513590.2018.1563883
26.
NaumovaI., & Castelo-BrancoC. (2018). Current treatment options for postmenopausal vaginal atrophy. International Journal of Women’s Health, 10, 387–395. https://doi.org/10.2147/IJWH.S158913
27.
ReedS. D., NewtonK. M., LaCroixA. Z., GrothausL. C., & EhrlichK. (2007). Night sweats, sleep disturbance, and depression associated with diminished libido in late menopausal transition and early post menopause: Baseline data from the herbal alternatives for menopause trial (HALT). American Journal of Obstetrics and Gynecology, 196(6), 593.e1–593.e7. https://doi.org/10.1016/j.ajog.2007.03.008
28.
SharmaS., TandonV. R., & MahajanA. (2007). Menopausal symptoms in urban women. Journal of Medical Education and Research, 9(1), 13–17.
29.
SidhuS., KaurA., & SidhuM. (2005). Age at menopause in educated women of Amritsar (Punjab). Journal of Human Ecology, 18, 49–51. https://doi.org/10.1080/09709274.2005.11905806
30.
SievertL. L., & Goode-NullS. K. (2005). Musculoskeletal pain among women of menopausal age in Puebla, Mexico. Journal of Cross-Cultural Gerontology, 20(2), 127–140. https://doi.org/10.1007/s10823-005-9087-3
31.
SturdeeD. (2014). Urogenital atrophy. Post Reprod Health, 20(2), 73–75. https://doi.org/10.1177/2053369114531908
32.
SturdeeD. W., & PanayN. (2010). Recommendations for the management of postmenopausal vaginal atrophy. Climacteric, 13(6), 509–22. https://doi.org/10.3109/13697137.2010.522875
33.
TanO., BradshawK., & CarrB. R. (2012). Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: An up-to-date review. Menopause, 19(1), 109–117.
34.
ThurstonR. C., & JoffeH. (2011). Vasomotor symptoms and menopause: Findings from the study of women’s health across the nation. Obstetrics and Gynecology Clinics of North America, 38(3), 489–501. https://doi.org/10.1016/j.ogc.2011.05.006
35.
VousouraE., SpyropoulouA. C., KoundiK. L., TzavaraC., VerdeliH., PaparrigopoulosT., AugouleaA., LambrinoudakiI., & ZervasI. M. (2015). Vasomotor and depression symptoms may be associated with different sleep disturbance patterns in postmenopausal women. Menopause, 22(10), 1053–1057. https://doi.org/10.1097/GME.0000000000000442
36.
World Health Organization (WHO). (1996). Research on the menopause in the 1990s(Report of a WHO scientific group, WHO Technical Report Series, 866). World Health Organization.
